What one share of Inventiva S.A. holds
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of MASH. We have a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
Inventiva S.A.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.03 |
|---|---|
| Profit | −$2.14 |
| Cash and investments | $0.60 |
| Debt | $0.36 |
| Book value | −$0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.18 | −$1.90 | — | — | — | $3.44 |
| 2019 | $0.33 | −$1.44 | — | — | — | $1.98 |
| 2020 | $0.01 | −$1.13 | — | — | — | $3.52 |
| 2021 | $0.13 | −$1.50 | — | — | — | $2.46 |
| 2022 | $0.31 | −$1.38 | — | — | — | $1.15 |
| 2023 | $0.42 | −$2.63 | — | — | — | −$0.68 |
| 2024 | $0.17 | −$3.33 | — | — | — | −$1.15 |
| 2025 | $0.03 | −$2.14 | — | — | — | −$0.17 |
Common questions about Inventiva S.A.
How much does one share of Inventiva S.A. earn?
Over its latest fiscal year, Inventiva S.A. lost $2.14 for each share on $0.03 of sales.
Does Inventiva S.A. pay a dividend?
Inventiva S.A. didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Inventiva S.A.’s book value per share?
Inventiva S.A.’s book value is negative (−$0.17 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of December 31, 2025.
How much cash and debt does each share of Inventiva S.A. have?
Each share of Inventiva S.A. has $0.60 of cash and investments and $0.36 of debt, as of December 31, 2025.
Has Inventiva S.A. bought back shares?
Inventiva S.A.’s share count rose about 809% from 2018 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.